title: [Cytokines as agents for the early pathogenetic therapy of radiation injuries. Their efficacy and mechanism of action].
abstract: It has been shown in experiments with three species of laboratory animals that an early administration (during the first hours following irradiation) of human recombinant interleukins 1 alpha and 1 beta separately (to mice, rats) or in combination with antibiotic therapy (dogs) substantially increases survivability, favours a more rapid regeneration of the cellular content of the bone marrow and peripheral blood, intensifies the processes of endogenous colony formation and DNA synthesis in the bone marrow and liver and lowers the expressivity of radiation-induced endotoxemia. The significance of using cytokines in the system of remedial measures in radiation pathology is discussed.
authors.affiliation: Research Institute for Military Medicine, Ministry of Defence of Russian Federation, St. Petersburg.
authors.forename: V I
authors.initials: VI
authors.lastname: Legeza
authors.forename: N G
authors.initials: NG
authors.lastname: Chigareva
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Abdul'
authors.forename: I Sh
authors.initials: ISh
authors.lastname: Galeev
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use*; D051379:Mice; D011833:Radiation Injuries, Experimental / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D051381:Rats; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D007375:Interleukin-1; D011837:Radiation-Protective Agents; D011994:Recombinant Proteins